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مرض الكبد الدهين غري  الكحولي - هل هو عامل 
اختطار ملرض الشريان التاجي؟ 
دراسة أولية جملموعة من سكان اهلند
مانوبرايا ثريوفاجندر، �شاهني خان ، دا�شتاجري �رشيف
امللخص: الهدف:  حتديد وجود مرض الكبد الدهني غير الكحولي عند مرضى الشريان التاجي . الطريقة: مت اختيار 149 مريضا أحيلوا إلى معهد القلب 
في منطقة باجنلور بالهند، في الفترة ما بني يناير 2007 إلى يونيو 2009، ومت تشخيصهم بإصابتهم مبرض الشريان التاجي . أربعة مرضى لم يشاركوا في 
الدراسة. مت أخذ عينات دم وريدي من املرضى املشاركني ومن عينة ضابطة (100 شخصا) من الذين ترددوا ألداء الفحص الطبي الدوري .متوافقة أعمارهم 
(I) والبروتني  البالزمينوجني  ملثبط منشط  املناعية  املقايسة  وإنزمي  األمني  ناقالت  أنزميات  الكبد شامال  لوظائف  روتيني  املرضى.  كذلك مت عمل فحص  مع 
الدهني  ناقلة أمني االالنني في املصل مت حتديد وجود مرض الكبد  أنزمي  َدى وقياس مستوى  طيطحُ الصَّ تَخنْ (ألفا) .وباستخدام  الورم  (ج) وعامل نخر  املتفاعل 
غير الكحولي عند مرضى الشريان التاجي. النتائج: وجد لدى مرضى الشريان التاجي الذين يعانون من مرض الكبد الدهني غير الكحولي مستويات مرتفعة 
املقايسة  إنزمي  (ألفا)  وكذلك  الورم  الضابطة. كانت مستويات عامل نخر  العينة  (AIC) مقارنة مبستويات  ارتفاع طفيف مبستوى  الكبد مع  أنزميات  من 
املناعية ملثبط منشط البالزمينوجني (I)  أعلى لدى مرضى الشريان التاجي والكبد الدهني غير الكحولي مقارنة مبستويات العينة الضابطة بدرجة معتدة 
إحصائيا (P<0.1,P<0.05) في كل من املرضى اإلناث والذكور.كان مستوى البروتني املتفاعل (ج) (P<0.01 في املموعتني) وكذلك حمض اليوريك أعلى 
في املموعتني من املرضى (P<0.05,P<0.01 في املرضى الذكور واإلناث على التوالي). كما كانت مستويات االديبونكتني  منخفضة بشكل كبير في املرضى 
املناعية ملثبط  املقايسة  إنزمي  التوالي). اخلالصة: زيادة مستوى كل من   واإلناث على  الذكور  املرضى  مقارنة بالعينة الضابطة   (P<0.05, P<0.001 في 
منشط البالزمينوجني (I) وعامل نخر الورم (ألفا) في املصل عكس حالة االستعداد لاللتهاب في هؤالء املرضى والذي قد يكون بسبب وجود مرض الكبد 
الدهني غير الكحولي، وهذا قد يساهم بشكل إضافي في نشوء أمراض القلب واألوعية الدموية. 
مفتاح الكلمات: مرض الكبد الدهني غير الكحولي، اديبو نكتني، مقاومة األنسولني، متالزمة االيض، مرض الشريان التاجي .
abstract: Objectives: The objective of this study was to identify the presence of non-alcoholic fatty liver disease 
(NAFLD) in patients with coronary artery disease (CAD).  Methods: 149 patients were selected, who had been 
referred to the Institute of Cardiology, Banglore, India, between January 2007 and June 2009 and diagnosed with 
CAD. Four patients did not participate in the study. Venous blood samples were taken from these cases, and age-
matched healthy controls who came for a master health check-up (N = 100). All were subjected to routine liver 
function tests including serum transaminases, enzyme immunoassays for plasminogen activator inhibitor I (PAI-I), 
C reactive protein (CRP), and tumour necrosis factor-alpha (TNF-α). Using ultrasonography and serum alanine 
aminotransferase (ALT) levels, the presence of NAFLD in CAD patients was reported. Results: CAD patients with 
NAFLD had significantly higher liver enzymes and marginally higher A1C levels compared to control subjects. 
Levels of TNF-α and PAI-I were higher in CAD patients with NAFLD compared to both female and male controls 
(P <0.1 and P <0.05). Levels of CRP (P <0.01 in both groups) and uric acid were increased in both group of patients 
(P <0.05 and P <0.01 in male and female patients, respectively). Levels of adiponectin were significantly reduced in 
the patients compared to the controls (P <0.05 and P <0.001) in male and female patients respectively. Conclusion: 
The increased serum levels of PAI-I and TNF-α reflected the proinflammatory status in these CAD patients which 
may be due to the presence of NAFLD. This could contribute additively to the development of cardiovascular events 
(CVD).
Keywords: Non-alcoholic fatty liver disease; Adiponectin; Insulin resistance; Metabolic syndrome; Coronary artery 
disease.
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Metabolic syndrome is frequently associated with a hypercoagulable condition, in that the coagulation 
system is switched towards a prothrombotic 
state, involving increased plasmatic coagulation, 
reduced fibrinolysis, decreased endothelial 
thromboresistance and predominantly platelet 
hyperactivity.1-6 All of these abnormalities in the 
coagulation and fibrinolytic systems may contribute 
to the development of cardiovascular complications 
in patients with metabolic syndrome.
Now, there is growing evidence that 
non-alcoholic fatty liver disease (NAFLD), a 
hepatic manifestation of the metabolic syndrome,7-8 
is strongly associated with a systemic pro-
inflammatory/procoagulant state, independently 
of shared cardiometabolic risk factors. Recently, we 
have shown that in non-alcoholic steatohepatitis 
(NASH) patients there is an increase in the levels of 
acute inflammatory markers, including C-reactive 
protein (CRP).9 There is evidence from another 
study that NASH is not simply a marker of the 
prothrombotic state in the metabolic syndrome, 
but is directly involved in its pathogenesis, possibly 
through the systemic release of proinflammatory 
and procoagulant factors from the steatotic/
inflamed liver.10 
Therefore, the present study was undertaken 
to evaluate the levels of plasminogen activator 
inhibitor-I (PAI-I), tumour necrosis factor-α 
(TNF-α), along with CRP in NAFLD patients in a 
local population in India.
Methods
The patients for the present study were among 
those referred between January 2007 and June 2009 
to the Institute of Cardiology, Banglore, India. A total 
of 149 patients with coronary artery disease (CAD) 
and NAFLD and 124 age-matched healthy control 
subjects who came for a master health check-up 
(N = 124) were selected for the present study. The 
presence of NAFLD in CAD cases was identified by 
serum alanine transaminase levels, serum aspartate 
aminotransferase/serum alanine aminotransferase 
(AST/ALT) ratio <1 and ultrasonographic findings. 
These cases were subjected to the following 
analyses. Venous blood was drawn in the morning 
after an overnight fast. Plasma liver function tests 
and other biochemical blood measurements were 
determined by standard laboratory procedures 
including enzyme immunoassays for PAI-I and 
TNF-α. All participants had negative serology for 
hepatitis B or C. Levels of low density lipoprotein 
(LDL) cholesterol was calculated by Friedwald’s 
equation. HbA1c (A1C) was measured by a high-
performance liquid chromatography analyser (HA-
8140, Menarini Diagnostics, Florence, Italy); the 
upper limit of normal for the laboratory was 5.9%. 
The respective intra- and inter-assay coefficients of 
variation (CVs) for the assays were: fasting plasma 
glucose (FPG) 1.4 and 2.0%; total cholesterol (TC) 
1.2% and 2.1%; triglyceride (TG) 1.5% and 3.6%; 
HDL-C 2.8% and 3.5%;  PAI-I 2.5% and 6.5%; TNF-
alpha  3.5% and 6.65%; HbA1C 1.9% and 2.1%.
The BMI was calculated by dividing weight in 
kilogrammes by height in metres squared. Waist 
Advances in knowledge
1. This study clarifies and contributes to the hypothesis that non-alcoholic fatty liver disease (NAFLD) could be a risk factor for coronary 
artery disease (CAD). 
2. The release of proinflammatory markers like tumour necrosis factor alpha (TNF-alpha) and plasminogen activator inhibitor- I (PI-I) 
may be causative factors that may initiate or contribute to the precipitation of coronary vascular events. 
3. The study confirms this supposition reflected by the increased serum levels of serum TNF-alpha and PAI-I in CAD patients with 
NAFLD. 
4. The study points out that every region and race must have their physical as well as biochemical parameters standardised for early 
detection and prevention of obesity related disorders
 Application to patient care
1. The study indicates that it would be prudent to look for markers other than lipid or diabetic profiles in patients with marked visceral 
obesity susceptible to coronary artery disease.
2.  It is shown that in India the prevalence of diabetes is very high due to obesity. It is known that a body mass index (BMI) of >25 is 
considered to be high for the Indian population, but considered normal for Western populations. Therefore, it is necessary to have a 
standardised record of BMI for all populations. 
3. It may be helpful to estimate serum aminotransferases to identify the presence of NAFLD in obese patients along with impaired glucose 
tolerance and hypertriglyceridemia (excluding other causes of fatty liver disease).  
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circumference was measured in a standing position 
at the level of the umbilicus. Blood pressure was 
assessed with a standard mercury manometer. 
Metabolic syndrome was defined according to 
criteria proposed by the National Cholesterol 
Education Program Adult Treatment Panel III (ATP 
III).11
Hepatic ultrasound scanning was performed 
in all participants by a trained operator who was 
blind to all clinical and laboratory characteristics of 
participants, using an Acuson 128-XP/10 scanner 
with a 3.5-MHz linear transducer. Hepatic steatosis 
was diagnosed by characteristic echo patterns, 
according to conventional criteria, i.e. evidence 
of diffuse hyperechogenicity of liver relative to 
kidneys, ultrasound beam attenuation, and poor 
visualisation of intrahepatic structures.12-14 Repeated 
measurements (that were performed on a subgroup 
of 100 patients) on the same subjects gave intra- 
and inter observer coefficients of variation within 
5%.9 The Ethics Review Committee of the Institute 
of Cardiology, Banglore, India approved the study 
project.
Data are presented as the means ± standard 
devitaion (SD) or frequencies. Skewed variables 
(serum triglyceride and liver enzyme levels) were 
logarithmically transformed to improve normality 
before analysis. Statistical analyses included the 
unpaired T test and the χ2 test with Yates’ correction 
for continuity (for categorical variables). 
Results
The clinical and biochemical characteristics of 
participants are shown in Table 1 for male and 
Table 2 for female subjects respectively. Because 
of the study design, case and control subjects 
were almost identical in terms of gender and age. 
The CAD patients with NAFLD had significantly 
higher liver enzymes and marginally higher A1C 
levels compared to control subjects. The proportion 
using antihypertensive drugs was higher among 
case subjects (~72 versus ~58%), whereas the 
proportion taking lipid-lowering or antiplatelet 
drugs was essentially similar in both male and 
female groups (~35 and ~50%, respectively).  CAD 
patients with NAFLD were older (P < 0.001), had 
higher liver enzymes (P < 0.001), and some tended 
to have a longer duration of diabetes (5.5 ± 2.5 years 
duration, P = 0.064). Gender, smoking status, LDL 
cholesterol, A1C, and diabetes treatment did not 
differ between the groups (not shown).
The levels of TNF-α and PAI-I were higher in 
CAD patients with NAFLD compared to normal 
control subjects (P <0.1 and P <0.05) in both female 
and male patients. The levels of CRP and uric acid 
were increased in both groups of patients (P <0.05 









Age (years) 47.7  ±  3.6 48.1  ±  14.6 0.982
Weight kg 66.1  ± 7.8 79 ± 11.9 <0.0001
BMI (kg/m2) 22.7 ± 2.4 27.8 ± 3.4 <0.0001
Waist-to-hip 
ratio (cm/cm),
0.87 ± 0.04 0.94 ± 0.04 <0.0001
Body fat mass 
(kg)




















47.1 ± 9.1 41.0 ± 7.9 0.005
HOMA 1.49 ± 0.71 3.04 ± 1.6 <0.0001
Uric acid  
(mg/dl)
5.6 ± 1.2 7.4 ± 1.7 0.05
ALT (IU/I) 20.7 ± 9.3 42.9 ± 29.1 , <0.0001
AST (IU/I) 19.7 ± 4.3 28.4 ± 14.2 <0.001
AST/ALT 
ratio
     >1      <1
CRP (mg/l) 3.72 ± 2.11 8.48 ± 2.75 <0.01
PAI-I   ng% 3.6 ± 1.2 7.9 ± 2.3 <0.01
TNF- α   pg/
ml% 6.66 ± 0.26 8.92 ± 0.44 <0.05
Adiponectin 
(ug/ml)
6.2 ± 3.4 4.5 ± 2.8 <0.05
Legend: NAFLD = Non-alcoholic fatty liver disease; CAD = coronary 
artery disease; BMI = body mass index; HDL = high density 
lipoproteins; HOMA = homeostasis model assessment; AST = serum 
aspartate aminotransferase; ALT = serum alanine aminotransferase; 
CRP = C reactive protein; PAI-I =plasminogen activator inhibitor I; 
TNF-α = tumor necrosis factor-alpha.
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and P <0.01 in male and female patients, respectively).
The levels of adiponectin were significantly reduced 
in the patients compared to the control  subjects 
(P <0.05 and P <0.001 in male and female patients 
respectively.) 
Discussion
The biological mechanisms by which NAFLD 
could contribute to accelerated atherosclerosis are 
still poorly known. Previous data suggest that  the 
relationship between NAFLD and increased risk 
of CAD is mostly reflected by hypertension and 
dyslipidemia.8,15,16 In this study, CAD patients with 
NAFLD show an  increase in proinflammatory 
markers TNF-α, CRP and PAI-I which may have 
additively contributed to future cardiovascular 
disease (CVD) events. This may be independent 
of metabolic syndrome and classic risk factors.10,11 
Conversely, several studies have consistently 
documented that insulin resistance predicts the 
incidence of CVD events10,11 and plays a pivotal 
role in the development of poor clinical outcomes 
in NAFLD patients.12-14 Thus, NAFLD in its more 
advanced forms might act as a stimulus for further 
increased whole-body insulin resistance and 
dyslipidemia, leading to accelerated atherosclerosis. 
This hypothesis is also partly validated by recent 
prospective studies demonstrating that raised liver 
enzymes independently predict the development 
of type 2 diabetes and other metabolic syndrome 
features.8,10,18 
Another possible atherogenic mechanism 
linking NAFLD and increased CVD risk is 
represented by increased oxidative stress and 
subclinical inflammation, which are thought to be 
causal factors in the progression from simple steatosis 
to more advanced forms of NAFLD.1,12,24 Reactive 
oxygen species derived from steatosis-stimulated 
fatty acid oxidation, attendant hepatocyte injury 
and cytokine release, and the ensuing 
proinflammatory milieu are likely to perpetuate 
the liver damage of NAFLD and add further 
atherogenic stimuli to the already high oxidative/
proinflammatory status that is closely related to 
the metabolic syndrome.8,10 In the present study, 
significant associations of NAFLD with impaired 
fibrinolytic activity were evidenced by increased 
levels of PAI-I and elevated plasma C-reactive 
protein; these associations were independent of age, 
BMI, blood pressure, lipids, and insulin resistance.20 
Decreased plasma levels of adiponectin, which is 
an adipose-secreted cytokine with antiatherogenic 
properties,21 may represent another possible 
mechanism linking NAFLD and CVD risk. It is 
shown that hypoadiponectinemia is closely 
correlated to NAFLD in obese individuals, 
independent of insulin resistance and other 
metabolic syndrome variables.22 Finally, 
accumulating evidence also exists that NAFLD 









Age (years) 47.1 ± 11.5 55.6 ± 8.5 -
Weight kg 55.8 ± 6.4 67.2 ± 8.9 <0.0001
BMI (kg/m2) 22.6 ± 2.5 27.1 ± 2.9 <0.0001
Waist-to-hip 
ratio (cm/cm), 0.87 ± 0.05 0.94 ± 0.05 <0.0001
Body fat mass 









71.5 ± 11.6 76.7 ± 10.4 0.015
Triglyceride 
(mg/dl) 98.7 ± 53.7 150.0 ± 73.2 <0.0001
HDL cholesterol 
(mg/dl) 57.2 ± 11.4 47.8 ± 9.0 <0.0001
HOMA 1.46 ± 0.8 2.56 ± 1.1 <0.0001
Uric acid (mg/
dl) 4.55 ± 2.40 7.55 ± 2055 <0.001
ALT (IU/I) 16.6 ± 6.8 68.0 ± 19.7 <0.0001
AST (IU/I) 20.0 ± 5.9 45.0 ± 10.7 <0.001
AST/ALT ratio - <1 -
CRP (mg/l) 3.22 ± 1.11   7.80 ± 2.75 <0.01
PAI – I  ng% 3.80 ± 1.2 6.90+2.3 <0.01
TNF- α pg/ml% 6.86+0.26 8.92+0.44 <0.05
Adiponectin 
(ug/ml  10.6 ± 4.8 7.2 ± 3.5
<0.0001
Legend: NAFLD = Non-alcoholic fatty liver disease; CAD = coronary 
artery disease; BMI = body mass index; HDL = high density 
lipoproteins; HOMA = homeostasis model assessment; AST = serum 
aspartate aminotransferase; ALT = serum alanine aminotransferase; 
CRP = C reactive protein; PAI-I = plasminogen activator inhibitor I; 
TNF-α = tumor necrosis factor-alpha.
Manopriya Thiruvagounder, Shaheen Khan, Dhastagir S Sheriff
Clinical and Basic Research | 225
could be linked to accelerated atherogenesis 
through the presence of abnormal lipoprotein 
metabolism. In NAFLD, hepatic apolipoprotein 
B-100 synthesis, a rate-determining step in hepatic 
very-low-density lipoprotein (VLDL) formation and 
in hepatocyte lipid export, is markedly reduced, and 
postprandial apolipoprotein B-100 responses are 
flat and strikingly dissociated from the concomitant 
increases of postprandial triglycerides.23,24 
Disturbances of VLDL assembly are an important 
factor in the natural history of NAFLD and can also 
result in increased levels of atherogenic triglyceride- 
and cholesterol-rich remnant particles.1,10,11 Small 
dense LDL particles, which are thought to be 
more atherogenic,8,10 could also be increased in 
NAFLD patients. However, detailed compositional 
lipoprotein studies should be performed in patients 
with NAFLD to prove this contention. 
The diagnosis of NAFLD was based on 
ultrasonography and exclusion of known aetiologic 
factors of chronic liver disease and serum 
transaminases levels. Indeed, it has been reported 
that the presence of >33% fat on liver biopsy is 
optimal for ultrasound detection of steatosis, 
although ultrasonography is not completely 
sensitive, particularly when hepatic fat infiltration 
is <33%.26 
Currently, it will be worthwhile to study 
whether improving NAFLD will ultimately prevent 
the development of CVD. However, it is notable 
that interventions that are known to be effective in 
preventing CVD among type 2 diabetic patients, 
including weight reduction and treatment with 
insulin-sensitising oral antidiabetic agents, may also 
improve NAFLD.1,8,14 
The fact that the study was done on a 
representative sample of CAD patients with low 
reported alcohol intake and with no exposure to 
hepatotoxic chemical or viral agents, and that a 
liver ultrasound for the diagnosis of NAFLD was 
performed on all participants, could enhance the 
validity of the present findings. 
Conclusion
In conclusion, the present study was done 
on proven CAD patients with NAFLD  to show 
the presence of NAFLD in CAD patients. The 
increased levels of TNF-α, PAI-I coupled with 
reduced adiponectin levels in CAD patients with 
NAFLD, along with dyslipidemia, establishes the 
fact that NAFLD could be an additive risk factor 
for abnormal coronary vascular events. It is to be 
noted that the average age of CAD with NAFLD 
patients was below fifty years in the males and 
above fifty years in the females.27 The lowered levels 
of adiponectin along with an increase in TNF-
alpha may be aggravating insulin resistance in these 
patients. Further studies are being carried out with 
more patients to understand the possible link of 
NAFLD to atherogenic mechanisms.
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